<DOC>
	<DOCNO>NCT01476059</DOCNO>
	<brief_summary>Prospective , parallel-group , randomize study evaluate compliance treatment child age 6 14 year old persistent moderate severe asthma , receive association Fluticasone 250 mcg/dose Salmeterol 50 mcg/dose twice day . ADERE PROJECT ( Pediatric )</brief_summary>
	<brief_title>Pediatric Study Evaluate Treatment Persistent Moderate Severe Asthma With Association Fluticasone 250 Mcg/Dose Salmeterol 50 Mcg/Dose - ADERE PROJECT</brief_title>
	<detailed_description>Objectives General : To evaluate compliance degree treatment asthmatic child , accord attention receive . Specific : 1 . To study asthmatic compliance treatment propose , aim association factor , : parent ' instruction , hospitalization , personal family history atopy , co-morbidities , severity disease use drug . 2 . To study asthmatic compliance treatment propose , associate impact quality life , though application specific questionnaire . Outcomes The main outcome , compliance , measure number dos use drug salmeterol combine fluticasone ( Seretide Diskus ) divide number dos foreseen time consider . The following consider secondary outcome : - Disease control , evaluate information questionnaire . - Regular medical attention seek , evaluate information questionnaire . - Additional resource event attack , increase weekly number nocturnal awaken number awakening per night , increase use rescue drug . - Improvement quality life . Casuistic Method Study group Asthmatic child age 6 14 year old sex , persistent mild , moderate sever asthma classify accord criterion III - Brazilian Consensus Asthma Management . Group I - Asthmatic child treat , give medical guidance therapeutic guidance telephone call every fifteen day parent guardian , perform trained professional . Group II - Asthmatic child treat , give medical guidance without telephone follow-up call parent guardian . Study Design This prospective , control , randomize , parallel-group study , inclusion 472 child present persistent moderate severe asthma . Our researcher develop study , perform Brazil , solely Clinical Research Center . The drug use accordance main International Consensus Asthma Treatment III - Brazilian Consensus Asthma Management , market year Brazil . During patient recruitment screening , parent guardian fill free inform consent form . At time , also give drug ( Seretide Diskus® 50/250 ) dos enough 90-day treatment , twice day , addition instruction use device apply drug guidance his/her physician act event attack . After study inclusion , study receive number randomly include him/her group 1 2 study . Patients include group 1 receive two type telephone call : A . Investigation telephone call - TI : make train health professional Centro de Pesquisa Clínica e Medicina Avançada , aim : presentation , data collection asthma , include demographic relevant clinical history ( detail asthma , previous exacerbation , drug use , etc ) , submission standardize check questionnaire ( questionnaire 1 - attachment 1 ) quality life questionnaire ( questionnaire 2 - attachment 2 ) . By 90 day , patient 's guardian receive last investigation telephone call ( TI -2 ) order apply quality life questionnaire standardize evaluation questionnaire ( questionnaire 1 - attachment 1 ) B . Compliance telephone call - TA : A specifically trained professional make follow-up telephone call every fifteen day , accord pre-established guide ( Attachment 4 ) , request patient answer question pursuant follow-up questionnaire ( attachment 3 ) clarify probable doubt drug application , however , without interfere treatment prescribed physician . Patients include group 2 receive Investigation Telephone call ( TI ) All telephone contact make person : mother , father guardian . By end week 12 , person responsible patient return , mail , drug Centro de Pesquisa Clínica e Medicina Avançada .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Salmeterol Xinafoate</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<criteria>Inclusion criterion : Signature informed consent form Age 6 14 year old Diagnosis persistent moderate severe asthma , accord III Brazilian Consensus Asthma Management . Home telephone available Exclusion criterion : Comorbidities may interfere study evaluation require continuous drug , e.g. , cardiopathy , gastroesophageal reflux diabetes . Continuous systemic corticosteroid use seven day The patient treat treated allergenspecific immunetherapy</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>14 Years</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>Treatment compliance</keyword>
	<keyword>Pediatric</keyword>
	<keyword>Asthma</keyword>
</DOC>